Harbourvest Partners’s Relay Therapeutics RLAY Stock Holding History

Harbourvest Partners’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-296,402	Closed	-$1.03M	–	15
2025 Q2	$1.03M	Hold	296,402	–	–	1.12%	7
2025 Q1	$777K	Hold	296,402	–	–	0.51%	9
2024 Q4	$1.22M	Hold	296,402	–	–	0.6%	12
2024 Q3	$2.1M	Hold	296,402	–	–	1.09%	9
2024 Q2	$1.93M	Hold	296,402	–	–	1.03%	12
2024 Q1	$2.46M	Hold	296,402	–	–	1.12%	10
2023 Q4	$3.26M	Hold	296,402	–	–	1.09%	13
2023 Q3	$2.49M	Hold	296,402	–	–	0.85%	18
2023 Q2	$3.72M	Hold	296,402	–	–	1.06%	13
2023 Q1	$4.88M	Hold	296,402	–	–	1.64%	11
2022 Q4	$4.43M	Hold	296,402	–	–	1.48%	12
2022 Q3	$6.63M	Hold	296,402	–	–	2.17%	11
2022 Q2	$4.96M	Hold	296,402	–	–	1.63%	14
2022 Q1	$8.87M	Hold	296,402	–	–	1.81%	11
2021 Q4	$9.1M	Hold	296,402	–	–	1.16%	13
2021 Q3	$9.35M	Hold	296,402	–	–	0.88%	14
2021 Q2	$10.8M	Hold	296,402	–	–	1.04%	11
2021 Q1	$10.2M	Buy	+296,402	New	+$12.9M	1.37%	11

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Harbourvest Partners's RLAY Position: Q3 2025 in Review

Harbourvest Partners sold out of Relay Therapeutics (RLAY) in Q3 2025, closing a stake of 296,402 shares — an estimated $1.03M sold.

Harbourvest Partners first reported a position in RLAY in Q1 2021 and held it in 18 quarters. The position peaked at $10.8M in Q2 2021. 199 funds tracked by Wall St. Rank hold RLAY as of Q3 2025.

Harbourvest Partners reported no remaining Relay Therapeutics position as of Q3 2025 after selling out during the quarter.
Harbourvest Partners sold 296,402 Relay Therapeutics shares in Q3 2025, an estimated $1.03M.
Harbourvest Partners first reported a position in Relay Therapeutics in Q1 2021 and held it in 18 quarters.
Harbourvest Partners's Relay Therapeutics position peaked at $10.8M in Q2 2021.
199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2025.

Based on Harbourvest Partners's 13F filing for Q3 2025, filed 14 Nov 2025.